Lilly restructuring (correction)
Lilly Exec VP-Science & Technology Steve Paul reports to CEO Sidney Taurel. In a story on Lilly's restructuring, "The Pink Sheet" incorrectly stated that Paul reports to President & Chief Operating Officer John Lechleiter (1"The Pink Sheet" Sept. 26, 2005, p. 19)...
You may also be interested in...
Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.